Literature DB >> 15693707

A new approach to pharmacological effects on ciliary beat frequency in cell cultures--exemplary measurements under Pelargonium sidoides extract (EPs 7630).

P Neugebauer1, A Mickenhagen, O Siefer, M Walger.   

Abstract

The ciliary beat frequency (CBF) is an important parameter of the defence mechanism of the mucociliary system. We present a new method to determine pharmacological effects on CBF in vitro. Ciliated cell cultures of human nasal epithelium were obtained from partial resection of hyperplastic inferior turbinates in rhinosurgery. An adherent monolayer culture of ciliated cells was present after 10 days in vitro. This study exemplary examines, if a special extract from the roots of Pelargonium sidoides (EPs 7630) has an effect on the CBF in vitro. The influence of three concentrations of the extract (1, 30, 100 microg/ml) was tested. EPs 7630 significantly and concentration-dependently increased CBF to 123% at 30 microg/ml and to 133% at 100 microg/ml compared to the equilibration phase (100%). After rinsing with extract-free medium the CBF of cultured cells returned to nearly the normal range. In future, drug manipulation of the CBF by local application of rhinologics could be a new therapeutical concept in the treatment of upper airway diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15693707     DOI: 10.1016/j.phymed.2003.11.005

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  10 in total

Review 1.  [Pelargonium sidoides-extract (EPs 7630): registration confirms efficacy and safety].

Authors:  Andreas Conrad; Herbert Kolodziej; Volker Schulz
Journal:  Wien Med Wochenschr       Date:  2007

Review 2.  Antimicrobial, Antiviral and Immunomodulatory Activity Studies of Pelargonium sidoides (EPs® 7630) in the Context of Health Promotion.

Authors:  Herbert Kolodziej
Journal:  Pharmaceuticals (Basel)       Date:  2011-10-10

Review 3.  Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children.

Authors:  Domenico Careddu; Andrea Pettenazzo
Journal:  Int J Gen Med       Date:  2018-03-08

4.  Evaluation of pharmacodynamic activities of EPs® 7630, a special extract from roots of Pelargonium sidoides, in animals models of cough, secretolytic activity and acute bronchitis.

Authors:  Yanyan Bao; Yingjie Gao; Egon Koch; Xin Pan; Yahong Jin; Xiaolan Cui
Journal:  Phytomedicine       Date:  2015-03-20       Impact factor: 5.340

5.  The herbal extract EPs® 7630 increases the antimicrobial airway defense through monocyte-dependent induction of IL-22 in T cells.

Authors:  Katrin Witte; Egon Koch; Hans-Dieter Volk; Kerstin Wolk; Robert Sabat
Journal:  J Mol Med (Berl)       Date:  2020-09-19       Impact factor: 4.599

Review 6.  The Relevance of Complementary and Integrative Medicine in the COVID-19 Pandemic: A Qualitative Review of the Literature.

Authors:  Georg Seifert; Michael Jeitler; Rainer Stange; Andreas Michalsen; Holger Cramer; Benno Brinkhaus; Tobias Esch; Annette Kerckhoff; Anna Paul; Michael Teut; Pirus Ghadjar; Jost Langhorst; Thomas Häupl; Vijay Murthy; Christian S Kessler
Journal:  Front Med (Lausanne)       Date:  2020-12-11

7.  Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials.

Authors:  Jia Yao; Yuan Zhang; Xian-Zhe Wang; Jia Zhao; Zhao-Jun Yang; Yu-Ping Lin; Lu Sun; Qi-Yun Lu; Guan-Jie Fan
Journal:  Front Public Health       Date:  2022-02-16

8.  Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis.

Authors:  W Kamin; V G Maydannik; F A Malek; M Kieser
Journal:  Acta Paediatr       Date:  2010-01-11       Impact factor: 2.299

9.  The Pelargonium sidoides Extract EPs 7630 Drives the Innate Immune Defense by Activating Selected MAP Kinase Pathways in Human Monocytes.

Authors:  Katrin Witte; Egon Koch; Hans-Dieter Volk; Kerstin Wolk; Robert Sabat
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

10.  Combining MucilAir™ and Vitrocell® Powder Chamber for the In Vitro Evaluation of Nasal Ointments in the Context of Aerosolized Pollen.

Authors:  Julia Metz; Katharina Knoth; Henrik Groß; Claus-Michael Lehr; Carolin Stäbler; Udo Bock; Marius Hittinger
Journal:  Pharmaceutics       Date:  2018-05-10       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.